Neogen Corp (NEOG): Cash & Equivalents

Annual figures by period end, from SEC filings.

$185.50M
As of 2026-05-31
+4.4%
3-year compound annual growth
+19.7%
5-year compound annual growth
+12.9%
10-year compound annual growth
2010-05-31: $22.81M2011-05-31: $35.84M2012-05-31: $49.05M2013-05-31: $50.03M2014-05-31: $40.67M2015-05-31: $66.06M2016-05-31: $55.26M2017-05-31: $77.57M2018-05-31: $83.07M2019-05-31: $41.69M2020-05-31: $66.27M2021-05-31: $75.60M2022-05-31: $44.47M2023-05-31: $163.24M2024-05-31: $170.61M2025-05-31: $129.00M2026-05-31: $185.50M$185.50M
2010-05-31 Cash & Equivalents (USD) 2026-05-31
Period endedCash & EquivalentsChange YoYSource filing
2026-05-31$185.50M+43.8%2026-07-30, Balance as of period end
2025-05-31$129.00M-24.4%2026-07-30, Balance as of period end
2024-05-31$170.61M+4.5%2025-07-30, Balance as of period end
2023-05-31$163.24M+267.1%2024-07-30, Balance as of period end
2022-05-31$44.47M-41.2%2023-08-15, Balance as of period end
2021-05-31$75.60M+14.1%2022-07-27, Balance as of period end
2020-05-31$66.27M+59.0%2021-07-30, Balance as of period end
2019-05-31$41.69M-49.8%2021-07-30, Balance as of period end
2018-05-31$83.07M+7.1%2020-07-30, Balance as of period end
2017-05-31$77.57M+40.4%2019-07-30, Balance as of period end
2016-05-31$55.26M-16.4%2018-07-27, Balance as of period end
2015-05-31$66.06M+62.4%2017-07-28, Balance as of period end
2014-05-31$40.67M-18.7%2016-07-29, Balance as of period end
2013-05-31$50.03M+2.0%2015-07-30, Balance as of period end
2012-05-31$49.05M+36.8%2014-07-30, Balance as of period end
2011-05-31$35.84M+57.2%2013-07-30, Balance as of period end
2010-05-31$22.81Mn/a2012-07-30, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Neogen Corp (NEOG)2026-05-31$185.50M+43.8%
Myriad Genetics Inc (MYGN)2025-12-31$149.60M+46.1%
Lantheus Holdings, Inc. (LNTH)2025-12-31$359.12M-60.7%
QuidelOrtho Corp (QDEL)2025-12-28$169.80M+72.7%
Idexx Laboratories Inc (IDXX)2025-12-31$180.07M-37.5%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$155.46M-17.8%
Alpha Teknova, Inc. (TKNO)2025-12-31$5.91M+59.4%
Immucell Corp (ICCC)2025-12-31$3.81M+1.3%
Aspira Women's Health Inc. (AWHL)2025-12-31$1.75M-0.8%

Compare NEOG, MYGN, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗